Polymorphic variants of drug-metabolizing enzymes alter the risk and survival of oral cancer patients

Daripally, Sarika; Peddi, Kiranmayi

doi:10.1007/s13205-020-02526-5

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 44 Such polymorphisms might be crucial for interindividual variability in drug response and toxicity or for increased disease risk. 45 For example, SULT1A1 polymorphism is associated with an increased risk of some cancers, such as breast cancer (especially in Asian patients), 46 gastric cancer, 47 tongue cancer in women, 48 and oral squamous cell carcinoma in Taiwanese patients with the H149Y haplotype. 49 CYP450s are critical in the stimulation of phase I drug metabolism 50 and detoxification as well as the elimination of common drugs.…”

Section: Adrs and Pharmacogenomicsmentioning

confidence: 99%

Structure–activity relationships and interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm

Thabet,

Alshar,

Alabdallah

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

Adverse drug reactions represent a major health burden because they cause notable patient morbidity and mortality. From this viewpoint, several strategies have been developed to prevent or reduce adverse drug reactions. One such strategy is the use of pharmacogenomics. Interindividual variability in drug response and adverse effects is mainly attributable to genetic variation in enzymes such as sulfotransferases and cytochrome P450s. The current narrative review discusses the relationship between the structure and activity of drugs. Specifically, the activity of drugs can be increased and/or their adverse effects can be reduced by altering specific positions in their structures.

show abstract